FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

P Narayan, S Wahby, JJ Gao, L Amiri-Kordestani… - Clinical cancer …, 2020 - AACR
Abstract On March 8, 2019, the FDA granted accelerated approval to atezolizumab in
combination with paclitaxel protein-bound for the treatment of adult patients with …

FDA Approval Summary: Atezolizumab as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

LN Mathieu, E Larkins, AK Sinha… - Clinical Cancer …, 2023 - AACR
Abstract On October 15, 2021, the FDA approved atezolizumab as adjuvant therapy in
patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have …

[HTML][HTML] FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer

M Royce, C Osgood, F Mulkey… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The US Food and Drug Administration approved abemaciclib in combination
with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone …

FDA Approval summary: Pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of Advanced/Metastatic PD-L1–high NSCLC

O Akinboro, E Larkins, LH Pai-Scherf, LN Mathieu… - Clinical Cancer …, 2022 - AACR
FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of
pembrolizumab and atezolizumab for similar indications as first-line treatment for patients …

FDA approval summary: mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer

A Dilawari, M Shah, G Ison, H Gittleman, MH Fiero… - Clinical Cancer …, 2023 - AACR
Abstract On November 14, 2022, the FDA granted accelerated approval to mirvetuximab
soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive …

US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic …

P Narayan, A Dilawari, C Osgood… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE The US Food and Drug Administration approved fam-trastuzumab deruxtecan-
nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresectable or metastatic …

[HTML][HTML] Immunotherapy biomarkers 2016: overcoming the barriers

JL Gulley, JA Berzofsky, MO Butler, A Cesano, BA Fox… - 2017 - Springer
This report summarizes the symposium,'Immunotherapy Biomarkers 2016: Overcoming the
Barriers', which was held on April 1, 2016 at the National Institutes of Health in Bethesda …

Musculoskeletal symptoms among cytotechnologists

SS Kalavar, KL Hunting - Laboratory Medicine, 1996 - academic.oup.com
We measured the prevalence of musculoskeletal symptoms among cytotechnologists in the
metropolitan Washington, DC, area. We surveyed cytotechnologists to assess the …

Haematopoietic cancer mortality among vehicle mechanics.

KL Hunting, H Longbottom, SS Kalavar… - Occupational and …, 1995 - oem.bmj.com
OBJECTIVE AND METHODS--This historical cohort study investigated causes of death
among car and mobile equipment mechanics in the District of Columbia's Department of …

FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

J Fallah, J Xu, C Weinstock, MH Brave… - Journal of Clinical …, 2024 - ingentaconnect.com
PURPOSE This article summarizes the US Food and Drug Administration (FDA) review of
the data leading to approval of olaparib plus abiraterone for the treatment of patients with …